Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 4/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.41 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 12/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nedocromil SCHEMBL20481863 | 1.00 | PDE5A (0.46) | PDE5AABCB11CYSLTR2CYSLTR1MEN1 | |
| Nedocromil SCHEMBL316743 | 1.00 | PDE5A (0.46) | PDE5AABCB11CYSLTR2CYSLTR1MEN1 | |
| Nedocromil SCHEMBL4611 | 0.99 | PDE5A (0.47) | PDE5AABCB11CYSLTR2CYSLTR1MEN1 | |
| Nedocromil SCHEMBL29406688 | 0.99 | PDE5A (0.47) | PDE5AABCB11CYSLTR2CYSLTR1MEN1 | |
| Nedocromil SCHEMBL667050 | 0.98 | PDE5A (0.46) | PDE5AABCB11CYSLTR2CYSLTR1MEN1 | |
| Nedocromil SCHEMBL2879046 | 0.98 | PDE5A (0.46) | PDE5AABCB11CYSLTR2CYSLTR1MEN1 | |
| Nedocromil SCHEMBL28341341 | 0.98 | PDE5A (0.46) | PDE5AABCB11CYSLTR2CYSLTR1MEN1 | |
| Nedocromil SCHEMBL17274068 | 0.96 | PDE5A (0.44) | PDE5AABCB11CYSLTR2CYSLTR1MEN1 | |
| Nedocromil SCHEMBL22028284 | 0.94 | PDE5A (0.44) | PDE5AABCB11CYSLTR2CYSLTR1MEN1 | |
| Nedocromil SCHEMBL17473185 | 0.93 | PDE5A (0.43) | PDE5AABCB11CYSLTR2CYSLTR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8568 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4058037-B1 | FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE | SPINALCYTE LLC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4590283-A1 | MUCOADHESIVE DRUG DELIVERY SYSTEMS AND METHODS OF USE | Madd Ophthalmics Ltd. (CA) | 2025-07-30 | — | — | EP | claimed |
| CN-119176762-A | Preparation method of nedocromil sodium key intermediate 3-acetamido-4, 6-diacetylphenol | 南京康立瑞生物科技有限公司 | 2024-12-24 | — | — | CN | claimed |
| CN-119080626-A | Preparation method for preparing nedocromil sodium key intermediate by using continuous flow technology | 南京康立瑞生物科技有限公司 | 2024-12-06 | — | — | CN | claimed |
| CN-118662629-A | Methods of treating inflammatory conditions | 瑞泽恩制药公司 | 2024-09-20 | — | — | CN | claimed |
| US-20240199751-A1 | METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST | SANOFI BIOTECHNOLOGY (FR) | 2024-06-20 | — | — | US | claimed |
| CN-110167963-B | Methods of treating inflammatory conditions | 瑞泽恩制药公司 | 2024-06-14 | — | — | CN | claimed |
| US-20240123168-A1 | PRODUCT DELIVERY DEVICES AND METHODS | MUSTAPHA JIHAD A (US) | 2024-04-18 | — | — | US | claimed |
| WO-2024059952-A1 | MUCOADHESIVE DRUG DELIVERY SYSTEMS AND METHODS OF USE | MADD OPHTHALMICS LTD. (CA) | 2024-03-28 | — | — | WO | claimed |
| EP-4324479-A2 | METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST | Sanofi Biotechnology (FR) | 2024-02-21 | — | — | EP | claimed |
| US-4868192-A | SKIN DISORDERS | FISONS PLC (GB) | 1989-09-19 | — | — | US | claimed |
| US-4866072-A | Method of treating cystic fibrosis | FISONS PLC (GB) | 1989-09-12 | — | — | US | claimed |
| EP-0318211-A1 | Nedocromil sodium compositions and methods for their preparation | FISONS plc (GB) | 1989-05-31 | — | — | EP | claimed |
| EP-0294940-A1 | Pharmaceutical compositions | FISONS plc (GB) | 1988-12-14 | — | — | EP | claimed |
| EP-0294914-A2 | Nedocromil for the treatment of dermatological disorders | FISONS plc (GB) | 1988-12-14 | — | — | EP | claimed |
| EP-0287193-A2 | Use of nedocromil sodium in the treatment of cystic fibrosis | FISONS plc (GB) | 1988-10-19 | — | — | EP | claimed |
| EP-0279121-A2 | Pharmaceutical compositions comprising an aqueous solution of a pyranoquinoline derivative | FISONS plc (GB) | 1988-08-24 | — | — | EP | claimed |
| US-4760072-A | Crystalline and contains bound water; treats reversible obstructive condition of airways in a mammal | FISONS, PLC (GB) | 1988-07-26 | — | — | US | claimed |
| EP-0241134-A1 | Pharmaceutical mixture comprising nedocromil or a salt thereof in combination with a bronchodilator | FISONS plc (GB) | 1987-10-14 | — | — | EP | claimed |
| EP-0162556-A1 | Novels forms and formulations of nedocromil sodium | FISONS plc (GB) | 1985-11-27 | — | — | EP | claimed |